The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | A trial by WM-NET investigating bendamustine, rituximab, and fixed-duration zanubrutinib in WM
Jeffrey Matous, MD, Colorado Blood Cancer Institute, Denver, CO, discusses ongoing and planned clinical trials for Waldenström macroglobulinemia (WM). He highlights the WM network (WM-NET) in the U.S., which is focused on novel trials, including one for treatment-naive patients using a combination of bendamustine, rituximab, and zanubrutinib. This trial aims to limit BTK inhibitor therapy to 15 months. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting: BeiGene.
